Table 1 Baseline characteristics.

From: Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION

Baseline characteristics

Asian population (N = 106)

Median age, years (range)

70.5 (52–89)

Sex, n (%)

Male

64 (60.4)

Smoking history,a n (%)

Current smoker

0

Former smoker

46 (43.4)

Never smoker

58 (54.7)

Histology, n (%)

Adenocarcinoma

84 (79.2)

Sarcomatoid

5 (4.7)

Squamous

7 (6.6)

Adenosquamous

3 (2.8)

Large cell

1 (0.9)

Other

6 (5.7)

ECOG PS, n (%)

0

28 (26.4)

1

78 (73.6)

Presence of BM at baseline,b n (%)

Yes

18 (17.0)

Line of therapy, n (%)

1L

50 (47.2)

2L

36 (34.0)

2L+

56 (52.8)

METex14 skipping detection, n (%)

T+

83 (78.3)

L+

48 (45.3)

T+ and L+

25 (23.6)

  1. 1L first line, 2L, second line, 2L+, second or later line, BM brain metastases, ECOG PS Eastern Cooperative Oncology Group performance status, L+ METex14 skipping detected in liquid biopsy, METex14 MET exon 14, T+ METex14 skipping detected in tissue biopsy.
  2. aSmoking history was missing in two patients.
  3. bIdentified at baseline (investigator or independent review).
Back to article page